- Home
- VERB vs APRE Comparison
VERB vs APRE Comparison
Compare VERB & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERB
- APRE
- Stock Information
- Founded
- VERB 2014
- APRE 2006
- Country
- VERB United States
- APRE United States
- Employees
- VERB N/A
- APRE N/A
- Industry
- VERB Other Consumer Services
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VERB Consumer Discretionary
- APRE Health Care
- Exchange
- VERB Nasdaq
- APRE Nasdaq
- Market Cap
- VERB 9.6M
- APRE 10.0M
- IPO Year
- VERB N/A
- APRE 2019
- Fundamental
- Price
- VERB N/A
- APRE $1.80
- Analyst Decision
- VERB Strong Buy
- APRE Strong Buy
- Analyst Count
- VERB 1
- APRE 2
- Target Price
- VERB $62.00
- APRE $15.50
- AVG Volume (30 Days)
- VERB 26.8K
- APRE 50.9K
- Earning Date
- VERB 08-13-2025
- APRE 08-11-2025
- Dividend Yield
- VERB N/A
- APRE N/A
- EPS Growth
- VERB N/A
- APRE N/A
- EPS
- VERB N/A
- APRE N/A
- Revenue
- VERB $2,193,000.00
- APRE $1,284,475.00
- Revenue This Year
- VERB $526.82
- APRE N/A
- Revenue Next Year
- VERB $45.45
- APRE N/A
- P/E Ratio
- VERB N/A
- APRE N/A
- Revenue Growth
- VERB 3125.00
- APRE 33.27
- 52 Week Low
- VERB $3.81
- APRE $1.41
- 52 Week High
- VERB $27.14
- APRE $5.01
- Technical
- Relative Strength Index (RSI)
- VERB 62.46
- APRE 49.58
- Support Level
- VERB $6.61
- APRE $1.64
- Resistance Level
- VERB $7.32
- APRE $1.81
- Average True Range (ATR)
- VERB 0.58
- APRE 0.15
- MACD
- VERB -0.00
- APRE -0.01
- Stochastic Oscillator
- VERB 91.94
- APRE 51.76
About VERB Verb Technology Company Inc.
Verb Technology Co Inc leader in interactive video-based sales applications, transforms how businesses attract and engage customers. VERB's Software-as-a-Service platform, based on its proprietary interactive video technology, comprises a suite of easy-to-use, subscription-based sales enablement software products. The segments of the company are MARKET.live and Go Fund Yourself, and it derives maximum revenue from MARKET.live segment.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.